Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer

Excerpt from the Press Release:

BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New York, NY for the development and worldwide commercialization rights relating to intellectual property for differentiating most potent immune cell from stem cells and large-scale manufacturing. Under the agreement, Cell BioEngines will utilize Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies, such as subtypes of dendritic cells (DC), NK cells, and macrophages, previously inaccessible to cancer patients.

The licensed technology is based on discoveries by Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research at Icahn Mount Sinai, Member of The Tisch Cancer Institute at Mount Sinai, and Member of The Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center together with Sreekumar Balan, PhD, Assistant Professor of Medicine (Hematology and Medical Oncology) in the Bhardwaj lab at Icahn Mount Sinai. Under the terms of the agreement, Icahn Mount Sinai will be eligible to receive an undisclosed upfront cash payment as well as additional milestones based on development, regulatory, and commercial milestones.

“Cell BioEngines is truly honored and excited to have this opportunity to advance Icahn Mount Sinai’s discovery to offer great hope for people with cancer and position Cell BioEngines to be a key player in the immune cell-based therapeutics area,” said Ajay Vishwakarma, DMD, MSc, MBA, Founder and CEO of Cell BioEngines Inc.

Click the button below to read the entire Press Release:

Continue Reading The Press Release